ABVC BioPharma, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 10, 2026, disclosing condensed consolidated financial statements and related disclosures.
Key Highlights
- Cash position: Cash and cash equivalents stood at $11,294 as of September 30, 2026, compared to $681,480 as of December 31, 2025.
- Restricted cash: Restricted cash was $0 as of September 30, 2026, down from $645,505 as of December 31, 2025.
- Total assets: Total assets were $20,296,072 as of September 30, 2026, compared to $21,822,203 as of December 31, 2025.
- Total current liabilities: Total current liabilities were $7,192,554 as of September 30, 2026, up from $6,923,976 as of December 31, 2025.
- Shares outstanding: As of November 9, 2026, there were 26,976,625 shares of common stock, par value $0.001 per share, issued and outstanding.
- Due to related parties: Amounts due to related parties increased to $1,478,178 as of September 30, 2026, from $865,704 as of December 31, 2025.
ABVC BioPharma Balance Sheet Position as of September 30, 2026
According to the filing, ABVC BioPharma, Inc. (NASDAQ:ABVC), a Nevada-incorporated biopharmaceutical company headquartered in Fremont, California, reported a sharp decline in cash and cash equivalents to $11,294 as of September 30, 2026, from $681,480 at December 31, 2025. Restricted cash, which was $645,505 at year-end 2025, was reported as $0 at the close of the third quarter.
The company's total current assets declined to $1,404,384 from $3,261,343 over the same period, according to the unaudited condensed consolidated balance sheets. Total assets fell to $20,296,072 from $21,822,203. Property and equipment, net, was reported at $12,825,164 as of September 30, 2026, compared to $12,835,409 at December 31, 2025. Long-term investments increased to $2,484,137 from $1,878,465 over the same period, the filing disclosed.
On the liabilities side, the filing reported that accrued expenses and other current liabilities rose to $4,533,972 from $4,161,629, and amounts due to related parties increased to $1,478,178 from $865,704. Convertible notes payable to third parties remained at $559,010, and convertible notes payable to related parties remained at $240,000 as of both dates. The company disclosed that the December 31, 2025 balance sheet figures are "revised." The filing noted 26,976,625 shares of common stock outstanding as of November 9, 2026.
What Was Disclosed
ABVC BioPharma filed its unaudited quarterly report covering the period ended September 30, 2026, disclosing balance sheet data showing a material reduction in cash and total current assets compared to December 31, 2025, alongside modest increases in current liabilities and related-party obligations.




Please wait processing your request...